Protagonist Therapeutics, Inc. research snapshot
PTGX AI stock analysis reads Protagonist Therapeutics as a commercial-stage royalty and milestone business in transition. PTGX closed at $136.64 on July 31, 2026, implying a market value of about $8.79 billion. ICOTYDE (icotrokinra) was approved by the FDA in March 2026 and launched in the United States, and rusfertide is under FDA priority review with an August 2026 target action date. Q1 2026 revenue was $56.37 million with $3.78 million of net income after a $50 million JNJ milestone, and cash and marketable securities stood at $620.3 million at March 31, 2026. The central PTGX AI stock forecast question is whether ICOTYDE and rusfertide royalties and milestones can justify a valuation that has risen about 150% over the past year. This page is informational research, not investment advice.
Current price
$136.64 close on July 31, 2026
Market cap
$8.79 billion reported, or $8.787 billion calculated from $136.64 x 64.31 million shares with a 0.03% variance
AI score
63 / 100
Rating
Constructive but extended. PTGX is executing on a launched ICOTYDE and a rusfertide FDA decision expected in August 2026, yet the stock trades near its 52-week high and above the average analyst price target, so upside is priced in and binary regulatory risk remains
Trend status
Strong long-term and short-term uptrend with price above rising 20-day, 50-day, 100-day and 200-day averages, though the stock is just below its July 20 high after consolidating
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Protagonist discovers and advances peptide medicines, then uses partnerships to fund development and monetize approvals through milestones and royalties. The model is improving as ICOTYDE becomes a launched product and rusfertide nears a decision, but revenue remains episodic and concentrated. | High |
| Moat | The moat is built from peptide discovery know-how, clinical data, intellectual property, regulatory progress, and partner capabilities. It is asset-specific rather than a broad customer, network, or distribution moat. | Medium |
| Management | CEO Dinesh V. Patel and CFO Asif Ali preserved about $620 million of cash and marketable securities at March 31, 2026 while advancing partnered and wholly owned programs. The April 2026 Takeda opt-out traded U.S. profit-sharing for a $200 million payment, a possible additional $200 million approval payment, up to $775 million in sales milestones, and 14% to 29% worldwide royalties. | Medium |
| Financial trend | FY2025 revenue fell 89% to $46.02 million after the 2024 upfront and milestone cycle, and the GAAP net loss was $130.15 million. Q1 2026 revenue was $56.37 million with $3.78 million of net income, but the quarter included a $50 million JNJ milestone and should not be annualized mechanically. TTM revenue is $74.06 million with a TTM net loss of about $114.7 million. | High |
| Valuation | At $136.64, trailing GAAP EPS is negative, forward P/E is about 30.6x on the FY2026 non-GAAP EPS estimate of $4.47, PS is about 16.5x on forecast 2026 revenue, and PB is about 13.4x. The 13-analyst average price target of $133.31 is slightly below the current price. | High |
| Technical trend | ChartMill rates PTGX 10 out of 10 technical with rising short-term and long-term trends, price above rising 20-day, 50-day, 100-day and 200-day averages, RSI 57.72, MACD -0.93, ADX 36.89, and ATR 4.68%. Support is $135.56 to $136.10 and $132.99, with resistance at $140.85 to $140.92. | Medium |
| Risk level | Risk is high. The valuation can re-rate sharply on the August 2026 FDA decision, label restrictions, clinical data, launch demand, partner choices, royalty timing, dilution, and concentration in a small number of programs. | High |
| AI confidence | The research has strong support for disclosed facts, but scenario outputs are sensitive to non-GAAP forward EPS, milestone timing, royalty assumptions, and the market multiple assigned to a biotech royalty stream. | Medium |
| Investment certainty | Investment certainty is lower than AI confidence. The business may create substantial value if both lead assets commercialize well, but a single regulatory, clinical, or commercial setback could change the thesis quickly, and the stock already trades above the average analyst target. | Low-medium |
PTGX AI stock forecast
The PTGX AI stock forecast uses a three-year sensitivity exercise with StockAnalysis's FY2026 forward non-GAAP EPS estimate of $4.47 as the starting point. With annual EPS growth of 25%, 10%, and negative 20% and terminal P/E assumptions of 35x, 25x, and 15x, financial_rigor.py produced reference values of $305.60, $148.70, and $34.30. These are scenario outputs, not analyst targets or promises. The model is fragile because the EPS anchor is non-GAAP and revenue depends on regulatory decisions, partner launches, milestones, and royalty rates.
$240 to $305 sensitivity reference
More likely if rusfertide receives FDA approval in August 2026 without a material label limitation, ICOTYDE launch builds through JNJ, royalties grow, additional indications expand the opportunity, and Protagonist converts milestones into durable per-share cash flow without heavy dilution.
$120 to $165 sensitivity reference
More likely if ICOTYDE royalties build gradually, rusfertide approval and milestone timing are broadly successful, but commercial uptake and the royalty stream take time. The base case assumes the market applies a moderate multiple to forward non-GAAP earnings rather than trailing GAAP losses.
$25 to $60 sensitivity reference
More likely if rusfertide is delayed, rejected, or label-limited, ICOTYDE uptake disappoints, a label or safety issue limits sales, partner priorities change, clinical programs consume cash, or the market stops capitalizing contingent milestones as recurring earnings.
PTGX AI technical analysis
PTGX AI technical analysis starts from the $136.64 July 31, 2026 close. The stock set a 52-week high of $143.29 on July 20, 2026 and has since consolidated between roughly $131 and $139. ChartMill assigns a technical rating of 10 out of 10 with rising short-term and long-term trends, price above rising 20-day ($135.56), 50-day ($119.55), 100-day ($110.27), and 200-day ($97.31) averages, RSI 57.72, MACD -0.93, ADX 36.89, and ATR 4.68%. Published support sits at $135.56 to $136.10 and $132.99, with deeper trend-line supports at $104.63, $99.89, and $91.45, and one resistance zone at $140.85 to $140.92.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $136.64 | StockAnalysis closing quote on July 31, 2026. The session range was $131.69 to $138.37 and volume was 548,601 shares. |
| Nearest support reference | $135.56 to $136.10 | ChartMill identifies this zone from multiple trend lines and important moving averages in multiple time frames. A break below it would show the pullback extending rather than a durable floor forming. |
| Secondary support reference | $132.99 | A horizontal support in the daily time frame. It is a reference from the current data cutoff, not a guaranteed support level. |
| Resistance reference | $140.85 to $140.92 | ChartMill lists this as the main resistance zone from multiple trend lines. A sustained break above it with volume would be needed to test the July high. |
| 52-week high reference | $143.29 | The July 20, 2026 intraday high. A close above it on catalyst confirmation would mark a fresh breakout rather than a retest. |
| Deeper support reference | $104.63 to $99.89 | Weekly and daily trend-line supports. These are deeper references if the move reverses and should not be confused with valuation floors. |
| Moving averages | 20-day $135.56; 50-day $119.55; 100-day $110.27; 200-day $97.31 | Price trades above all four, which are rising, a bullish alignment. The 20-day average is only slightly below price, so the near-term average is being tested. |
| Momentum | RSI 57.72; MACD -0.93; Stochastics 58.7 | Daily indicators are neutral. Weekly RSI at 74.91 and weekly Stochastics at 90.75 are in overbought territory after the recent run. |
| Volume and volatility | 548,601 shares on July 31; ATR 4.68% | The 20-day average volume is roughly 700,000 to 730,000 shares. ChartMill classifies ATR as medium volatility, while biotech catalysts can create larger gaps. |
| Invalidation reference | Sustained close below $132.99 | A close below the $132.99 support would weaken the near-term structure. A close below the late-June $118.31 to $122.48 area would mark a much deeper deterioration, subject to new clinical or regulatory information. |
PTGX AI trading strategy
The PTGX AI trading strategy is a rules-based research framework, not personalized advice. It should be paired with a live chart, an FDA and earnings calendar, position sizing, and fresh SEC filings because PTGX can gap on clinical, regulatory, partner, and milestone news. Q2 2026 results were scheduled for August 3 to August 5, 2026.
Wait for price to reclaim and hold above the $140.85 to $140.92 resistance reference with sustained volume, ideally confirmed by the rusfertide FDA decision and positive ICOTYDE launch and royalty data. A breakout without clarity on the approval, label, or royalty economics is not enough by itself.
A failed breakout followed by a close below $135.56 weakens the setup. A sustained close below $132.99 is a broader trend warning.
If price holds the $135.56 to $136.10 zone or the $132.99 support, monitor whether the pullback is accompanied by unchanged regulatory timing, positive partner launch data, stable cash, and no new dilution. The setup is only a test of risk and reward, not a reason to buy a falling stock.
Do not average down solely because price reaches a historical level. Reassess immediately if FDA timing, safety data, partner strategy, cash use, or share count worsens.
Track the rusfertide FDA action and label, ICOTYDE prescription and royalty trends, JNJ and Takeda milestone receipts, royalties by indication, cash runway, R&D spending, share count, PN-881 progress, and the PN-477 and PN-458 obesity programs.
Reduce confidence if revenue remains milestone-heavy, royalties lag launch expectations, new programs expand cash burn without validation, or the company needs capital at an unfavorable price.
Investment research summary
Protagonist creates value by discovering and advancing peptide medicines, then partnering with larger companies that fund late-stage development, regulatory work, and global commercialization. ICOTYDE is now approved and launched with JNJ, and rusfertide has an NDA under priority review. The economic customer is the pharmaceutical partner that pays for access to differentiated drug candidates and future commercial rights.
The moat is asset-level intellectual property, peptide design and development know-how, clinical evidence, regulatory progress, and partner relationships with JNJ and Takeda. It can be valuable when a candidate succeeds, but it is not a permanent corporate moat. Patent life, competing therapies, safety findings, and clinical reproducibility can narrow it quickly.
The failure path is concentrated: rusfertide could face a delay, rejection, narrow label, or weak adoption; ICOTYDE royalties could arrive slower than investors expect; partners could change priorities; and wholly owned programs could consume cash without producing a clinical winner. The stock can fall even after good science if the market had already priced in approval and launch success.
Dinesh V. Patel is President and CEO, and Asif Ali is Executive Vice President and CFO. Cash and marketable securities were $620.3 million at March 31, 2026, down from $646.0 million at December 31, 2025. The April 2026 Takeda opt-out exchanged U.S. profit-sharing exposure for a $200 million payment, a possible additional $200 million approval payment, up to $775 million in sales milestones, and 14% to 29% worldwide royalties. The key test is whether this reduces operating risk while preserving upside without excessive dilution.
The long-term opportunity spans targeted oral immunology, rare hematology, obesity medicines, and peptide drug delivery. ICOTYDE is the first approved targeted oral peptide for moderate-to-severe plaque psoriasis, and rusfertide addresses polycythemia vera. The industry is attractive but crowded, and clinical differentiation, reimbursement, safety, manufacturing, and regulatory execution determine who captures value.
At $136.64, PTGX trades on future success rather than current GAAP earnings. The financial_rigor.py check produced negative trailing P/E, about 13.4x book value, about 16.5x forward revenue, and about 30.6x forward non-GAAP EPS. The 13-analyst average target of $133.31 is below the current price, so the margin of safety must come from cash, partnered economics, and the probability-weighted value of approvals, not from current operating multiples.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| PTGX closing price and recent volume | $136.64 close on July 31, 2026; 548,601 shares traded | StockAnalysis historical price data | August 3, 2026 |
| Market cap and shares | $8.79B market cap; 64.31M shares outstanding | StockAnalysis statistics and market-cap calculation | August 3, 2026 |
| FY2025 revenue and net income | $46.02M revenue; $130.15M GAAP net loss | SEC 2025 Form 10-K and StockAnalysis financials | August 3, 2026 |
| FY2025 operating cash flow and free cash flow | $57.67M operating cash flow; $56.08M free cash flow | StockAnalysis cash flow statement | August 3, 2026 |
| Cash and marketable securities | $646.0M at December 31, 2025; $620.3M at March 31, 2026 | SEC 2025 Form 10-K and Q1 2026 Form 10-Q | August 3, 2026 |
| Q1 2026 results | $56.37M collaboration revenue; $3.78M net income; $50M JNJ milestone | SEC Q1 2026 Form 10-Q | August 3, 2026 |
| ICOTYDE economics | FDA approved March 18, 2026; 6% to 10% worldwide royalties and up to $580M future milestones | Protagonist Q1 2026 corporate update | August 3, 2026 |
| Rusfertide regulatory and opt-out terms | NDA priority review with an August 2026 PDUFA date; $200M opt-out payment, possible $200M approval payment, and 14% to 29% worldwide royalties | SEC Q1 2026 Form 10-Q and Protagonist Q1 2026 corporate update | August 3, 2026 |
| Forward earnings reference | FY2026 average forecast revenue $529.83M and non-GAAP EPS $4.47 | StockAnalysis analyst forecast page | August 3, 2026 |
| Analyst consensus and price target | Strong Buy; average target $133.31 across 13 analysts; low $110, high $172 | StockAnalysis analyst forecast page | August 3, 2026 |
| Technical snapshot | Technical rating 10/10; RSI 57.72; MACD -0.93; ATR 4.68%; support $135.56 to $136.10 and $132.99; resistance $140.85 to $140.92 | ChartMill technical analysis | August 3, 2026 |
This PTGX AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are scenario outputs based on available data and assumptions that can be wrong. Verify current prices, filings, clinical and regulatory updates, technical levels, tax rules, and personal suitability before making any financial decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
